{"gene":"CXCL10","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2002,"finding":"The NMR structure of IP-10/CXCL10 was solved, revealing an unusual structural feature that may explain its ability to bind both CXCR3 and CCR3. The surface of IP-10 that interacts with the N-terminus of CXCR3 was defined and involves a hydrophobic cleft formed by the N-loop and 40s-loop region, similar to IL-8; an additional interaction region was identified at the N-terminus and 30s-loop of IP-10.","method":"NMR spectroscopy with CXCR3 N-terminal peptide titration","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure determination with functional receptor-binding surface mapping using peptide titration; single lab but multiple orthogonal validations","pmids":["12173928"],"is_preprint":false},{"year":2003,"finding":"Mutational analysis of murine IP-10/CXCL10 identified distinct but partially overlapping CXCR3 and heparin (GAG) binding sites. Arg-22 had the largest effect on heparin binding; residues Arg-20, Ile-24, Lys-26, Lys-46, and Lys-47 also contributed. Arg-8 (N-terminal, preceding first cysteine) was critical for CXCR3 signaling. GAG-deficient CHO cells showed that heparin/GAG binding is not required for CXCR3 binding and signaling.","method":"Extensive alanine-exchange mutagenesis with heparin binding, CXCR3 binding, chemotaxis, Ca2+ flux, and CXCR3 internalization assays; GAG-deficient CHO cell experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro mutagenesis with multiple orthogonal functional readouts (binding, signaling, chemotaxis, Ca2+ flux); extensive mutant panel","pmids":["12571234"],"is_preprint":false},{"year":2008,"finding":"Crystal structure of mouse IP-10/CXCL10 revealed a novel tetrameric association in which two conventional CXC chemokine dimers associate through their N-terminal regions to form a 12-stranded elongated beta-sheet. This tetramer differs from previously described tetramers of human IP-10, platelet factor 4, and NAP-2. Two heparin-binding sites were identified at the interface of each of the two beta-sheet dimers.","method":"X-ray crystallography","journal":"Acta crystallographica. Section D, Biological crystallography","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure determination; single study but direct structural evidence","pmids":["18560148"],"is_preprint":false},{"year":1997,"finding":"Recombinant human IP-10 (rIP-10) has no chemotactic activity on neutrophils but specifically targets lymphocytes, acting as a chemotactic factor for stimulated (but not resting) T cells. rIP-10 and rHuMig show reciprocal desensitization on activated T cells and share the receptor CXCR3. rIP-10 also inhibits neovascularization, inhibits hematopoietic progenitor cells, and exerts anti-tumor effects.","method":"Recombinant protein chemotaxis assays in vitro and in vivo; receptor desensitization assays","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — recombinant protein functional assays replicated across in vitro and in vivo settings, CXCR3 receptor sharing demonstrated by cross-desensitization","pmids":["9060447"],"is_preprint":false},{"year":2009,"finding":"CXCL10 impairs beta cell viability and function through TLR4 signaling rather than CXCR3. CXCL10 treatment of human islets decreased beta cell viability, impaired insulin secretion, and decreased insulin mRNA. Mechanistically, CXCL10 induced sustained activation of Akt and JNK and cleavage of PAK-2, switching Akt signals from proliferation to apoptosis. CXCR3 blockade did not abolish these effects, implicating TLR4 as a binding partner/receptor for CXCL10 in beta cells.","method":"Recombinant CXCL10 treatment of human islets; CXCR3 blockade experiments; western blotting for Akt, JNK, PAK-2 signaling","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab with multiple signaling readouts and receptor specificity tested, but TLR4 as direct binding partner not formally confirmed by binding assay","pmids":["19187771"],"is_preprint":false},{"year":2011,"finding":"CXCL10/CXCR3 signaling regulates synovial fibroblast (FLS) invasion in rheumatoid arthritis via an autocrine/paracrine mechanism. CXCL10 treatment increased FLS invasiveness 2-fold; anti-CXCR3 antibody and CXCR3 inhibitor AMG487 reduced invasiveness up to 77% in DA rat FLS and 58% in RA FLS. CXCR3 blockade reduced MMP-1 levels by 65%, inhibited intracellular calcium influx, and interfered with actin cytoskeleton reorganization and lamellipodia formation.","method":"Matrigel invasion assay, anti-CXCR3 antibody and pharmacological inhibitor treatment, MMP-1 ELISA, intracellular calcium measurement, actin cytoskeleton imaging","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays (invasion, MMP, Ca2+ flux, cytoskeleton), reciprocal pharmacological and antibody inhibition, single lab","pmids":["21811993"],"is_preprint":false},{"year":2012,"finding":"CXCL10 inhibits angiogenesis through CXCR3-dependent mechanisms involving cAMP production and PKA activation (inhibiting cell migration) and inhibition of VEGF-mediated m-calpain activation. A 21-amino-acid C-terminal alpha-helical fragment of IP-10 (residues 77-98, IP-10p) recapitulates these anti-angiogenic effects, inhibiting VEGF-induced endothelial motility and tube formation in vitro and vessel formation in vivo; CXCR3 neutralizing antibody blocked IP-10p effects.","method":"In vitro endothelial motility and tube formation assays; in vivo Matrigel plug assay; CXCR3 neutralizing antibody blockade; cAMP measurement; PKA activity assay; calpain activity assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo assays with defined peptide fragment and receptor blockade; single lab","pmids":["22815829"],"is_preprint":false},{"year":2015,"finding":"CXCL10 triggers early microglial activation following oligodendrocyte apoptosis in the cuprizone model. CXCL10-deficient mice showed significantly reduced early microglial activation and ameliorated cuprizone toxicity. In vitro, recombinant CXCL10 induced migration and a pro-inflammatory phenotype in cultured microglia without affecting phagocytic activity or proliferation. In situ hybridization showed Cxcl10 mRNA is mainly expressed by astrocytes (and some oligodendrocytes) under these conditions.","method":"CXCL10-deficient knockout mice; in vitro recombinant CXCL10 treatment of microglia; genome-wide gene expression; in situ hybridization","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse model with defined phenotype, in vitro mechanistic follow-up with recombinant protein, multiple orthogonal methods; single lab","pmids":["25725102"],"is_preprint":false},{"year":2017,"finding":"CXCL10 suppresses hem- and lymph-angiogenesis in inflamed corneas through suppression of angiogenic factors including VEGFa, VEGFc, and MMP-13 in vivo. AAV9-driven epithelial CXCL10 expression suppressed infection- and inflammation-induced angiogenesis; CXCL10 or CXCR3 neutralization promoted angiogenesis. Inhibition of MMP-13 (but not TIMPs) attenuated neovascularization, placing MMP-13 downstream of angiogenic signals but not upstream of CXCL10.","method":"AAV9 vector-driven CXCL10 overexpression; CXCL10 and CXCR3 neutralizing antibodies; MMP-13 inhibitors; in vivo mouse corneal model","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic/pharmacological manipulation with multiple readouts; single lab, pathway hierarchy tested","pmids":["28623423"],"is_preprint":false},{"year":2018,"finding":"EZH2 and G9a cooperatively repress CXCL10 expression in idiopathic pulmonary fibrosis fibroblasts through histone H3K27 trimethylation and H3K9 methylation at the CXCL10 promoter. EZH2 and G9a physically interact; knockdown of either reduces the other's histone mark and restores CXCL10 expression. TGF-β1 induces this epigenetic repression. Re-ChIP and proximity ligation assays confirmed co-occupancy of EZH2 and G9a at the CXCL10 promoter.","method":"Chromatin immunoprecipitation (ChIP), Re-ChIP, proximity ligation assay, siRNA knockdown, pharmacological inhibition, promoter analysis","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP/Re-ChIP with mutagenesis-equivalent knockdown and multiple orthogonal methods (PLA, pharmacological inhibition), single lab","pmids":["29053336"],"is_preprint":false},{"year":2017,"finding":"IP-10/CXCL10 gene induction in pancreatic beta cells is regulated by NFAT signaling via calcineurin-dependent pathways in response to oxidative or inflammatory stress. Sustained NFAT and p300 histone acetyltransferase association with the IP-10 gene promoter requires p38 and JNK MAPK activity, which differentially regulate IP-10 expression and protein release.","method":"Transgenic mouse studies, in vitro signaling pathway analysis, NFAT/p300 ChIP, MAPK inhibition","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple approaches (transgenic mice, ChIP, pharmacological inhibition) in single lab","pmids":["28855240"],"is_preprint":false},{"year":2019,"finding":"Leishmania major virulence factor GP63 (glycoprotein-63) cleaves CXCL10 after amino acid A81 at the base of its C-terminal alpha-helix, inactivating its chemotactic function. This cleavage is specific to CXCR3-binding chemokines (CXCL10 and homologs) but not to distantly related chemokines (CXCL8, CCL22). The cleaved CXCL10 cannot signal through CXCR3 and fails to support T cell chemotaxis in vitro.","method":"In vitro protease cleavage assay, site identification by sequencing, T cell chemotaxis assay, CXCR3 signaling assay","journal":"Frontiers in cellular and infection microbiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of protease cleavage with exact cleavage site identification, functional consequence confirmed by T cell chemotaxis assay","pmids":["31440475"],"is_preprint":false},{"year":2018,"finding":"DPP4 (CD26) can N-terminally truncate CXCL10 to generate an antagonist form capable of binding CXCR3 but unable to induce signaling. In tuberculosis lesions, higher levels of antagonist CXCL10 and reduced DPP4 enzyme activity were found in plasma of TB patients; DPP4-positive T cells were associated with CXCL10-secreting multinucleated giant cells, suggesting membrane-bound DPP4 can inactivate secreted CXCL10 locally.","method":"Simoa digital ELISA for agonist/antagonist CXCL10, DPP4 enzyme activity assay, immunohistochemistry, confocal microscopy","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — distinct quantification of agonist vs antagonist forms, enzyme activity measurement, and spatial co-localization; single lab","pmids":["30026741"],"is_preprint":false},{"year":2014,"finding":"MRP8/MRP14 (S100A8/A9), an endogenous DAMP, induces IP-10/CXCL10 expression in monocytes/macrophages via TLR4 and TRIF (not MyD88). Full IP-10 induction requires synergistic activation of NF-κB and IRF3 transcription factors. MRP8/MRP14-induced chemotaxis of CXCR3+ cells was dependent on IP-10 production.","method":"THP-1 cell stimulation, TLR4/MyD88/TRIF pathway dissection, NF-κB and IRF3 reporter/western blot, neutralizing antibody, in vivo mouse trauma/hemorrhagic shock model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — signaling pathway dissection with receptor knockdown/blockade and in vivo validation; single lab","pmids":["25342131"],"is_preprint":false},{"year":2007,"finding":"In human keratinocytes, IFN-γ induces IP-10 mRNA accumulation in a time- and dose-dependent manner. Superexpression occurs with IFN-γ combined with TNF-α or IL-1. Nuclear run-on experiments showed constitutively high IP-10 gene transcription in unstimulated keratinocytes not further increased by IFN-γ/TNF-α, indicating post-transcriptional regulation. PKC inhibitor H7 decreased IP-10 mRNA accumulation, implicating PKC in IP-10 expression regulation.","method":"RT-PCR, Northern blot, nuclear run-on transcription assay, HPLC protein isolation, ELISA, PKC inhibitor treatment","journal":"Archives of dermatological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — nuclear run-on assays to distinguish transcriptional vs post-transcriptional regulation, pharmacological pathway dissection; single lab","pmids":["9705166"],"is_preprint":false},{"year":1999,"finding":"IP-10 (CXCL10) and Mig (CXCL9) sharing of receptor CXCR3 was confirmed in glomerulonephritis; IP-10 induced intracellular Ca2+ influx in mesangial cells expressing CXCR3 and directly induced mesangial cell proliferation.","method":"Flow cytometry (CXCR3 expression), intracellular Ca2+ flux measurement, cell proliferation assay with recombinant IP-10","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional receptor activation (Ca2+ flux) and proliferation assay with recombinant ligand; single lab","pmids":["10589690"],"is_preprint":false},{"year":2020,"finding":"CXCL10/CXCR3 signaling in dorsal root ganglion (DRG) neurons increases neuronal excitability and contributes to neuropathic pain. CXCL10 increased the number of action potentials in DRG neurons via CXCR3 (not increased in Cxcr3-/- neurons). CXCL10 activated p38 and ERK in DRG neurons; p38 inhibitor SB203580 decreased CXCL10-induced APs. Intra-DRG Cxcr3 shRNA attenuated spinal nerve ligation-induced mechanical allodynia and heat hyperalgesia.","method":"Electrophysiology (action potential recording), Cxcr3 knockout mice, shRNA knockdown, p38/ERK western blot, pharmacological inhibition","journal":"Neuroscience bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — electrophysiology with genetic knockout and shRNA confirmation, signaling pathway identified with pharmacological inhibition; single lab","pmids":["33196963"],"is_preprint":false},{"year":2009,"finding":"Infected CXCL10-/- or CXCR3-/- mice demonstrated reduced accumulation of trypanosomes and T cells in the brain parenchyma during experimental African trypanosomiasis, while parasitemia levels were similar to wild-type, establishing that IFN-γ-dependent CXCL10/CXCR3 signaling is critical for brain parenchymal T cell and parasite accumulation specifically.","method":"CXCL10-/- and CXCR3-/- knockout mouse infection model, tissue cell quantification, parasitemia measurement, CXCL10 ELISA","journal":"The Journal of infectious diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent knockout models (CXCL10-/- and CXCR3-/-) with consistent phenotype; single lab","pmids":["19827943"],"is_preprint":false},{"year":2017,"finding":"CXCL10 accelerates epithelial-mesenchymal transition (EMT) and metastasis of hepatocellular carcinoma cells via activation of MMP-2 expression. CXCL10 overexpression enhanced migration, invasion, and metastasis in vitro and in vivo; CXCL10 silencing inhibited these. Microarray analysis identified MMP-2 as a downstream factor of CXCL10.","method":"shRNA knockdown, overexpression, Transwell migration/invasion assay, in vivo xenograft, microarray gene expression analysis","journal":"American journal of translational research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, microarray-based identification of MMP-2 as downstream target without direct mechanistic validation of the CXCL10→MMP-2 connection","pmids":["28670372"],"is_preprint":false},{"year":2019,"finding":"Viperin regulates chondrogenic differentiation via CXCL10 secretion, which in turn modulates TGF-β/SMAD2/3 signaling activity in chondrocytes. Disturbances in this viperin-CXCL10-TGF-β/SMAD2/3 axis were observed in cartilage-hair hypoplasia (CHH) chondrocytic cells.","method":"siRNA knockdown, overexpression, ELISA, label-free MS proteomics, promoter reporter assays, immunoblotting","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (proteomics, siRNA, ELISA, reporter assays) linking viperin→CXCL10→TGF-β/SMAD2/3 axis; single lab","pmids":["30718282"],"is_preprint":false},{"year":2017,"finding":"JAK2V617F mutation drives cell-autonomous CXCL10 expression through NF-κB signaling. Pharmacological inhibition of mutated JAK2 kinase inhibits CXCL10 expression. NFκB is activated downstream of JAK2V617F and directly induces CXCL10 transcription, as demonstrated by luciferase reporter assays and ChIP.","method":"Cytokine array, qPCR, JAK inhibitor treatment, NF-κB luciferase reporter, ChIP, western blotting, immunofluorescence; Ba/F3 cells lacking CXCL10 receptor to exclude autocrine signaling","journal":"Journal of cancer research and clinical oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (reporter, ChIP, pharmacological inhibition) demonstrating JAK2V617F→NF-κB→CXCL10 axis; single lab","pmids":["28233092"],"is_preprint":false},{"year":2017,"finding":"PERK pathway positively regulates CXCL10 expression under ER stress conditions, while XBP1 (activated by IRE1α) negatively regulates it. PERK knockdown attenuated ER stress-induced CXCL10 mRNA expression associated with decreased NF-κB RelA and STAT3 phosphorylation; XBP1 knockdown enhanced CXCL10 expression with increased NF-κB RelA and STAT3 phosphorylation. Blockade of NF-κB or STAT3 markedly diminished CXCL10 expression.","method":"siRNA knockdown of PERK and XBP1, NF-κB and STAT3 pharmacological inhibition, RT-PCR, ELISA, western blot","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown of pathway components with multiple downstream readouts confirming NF-κB and STAT3 as mediators; single lab","pmids":["28065589"],"is_preprint":false},{"year":2022,"finding":"CXCL10 induces CCL12 expression in alveolar macrophages (AMs) by activating both CXCR3 and TLR4, promoting premetastatic niche formation. CXCR3/TLR4 deficiency or inhibition reduces CCL12 expression and subsequent monocytic MDSC recruitment. Ube2o is a negative modulator of CXCL10-induced CCL12 expression; its downregulation under tumor conditions enhances TAK1-NF-κB/ERK/JNK signaling and CXCL10-induced CCL12 expression by promoting TRAF6 polyubiquitination and inhibiting DDX3X degradation.","method":"CXCR3/TLR4 knockout mice, siRNA, pharmacological inhibition, western blot for signaling intermediates, in vivo lung metastasis model","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dual receptor (CXCR3 and TLR4) signaling demonstrated with knockouts and pharmacological inhibition, mechanistic pathway defined; single lab","pmids":["35398531"],"is_preprint":false},{"year":2020,"finding":"Human chorionic gonadotropin (hCG) inhibits CXCL10 expression in decidual stromal cells by inducing H3K27me3 histone methylation at Region 4 of the CXCL10 promoter, mediated through EZH2 (a member of the PRC2 complex). This regulation has functional consequences for CD8 cell recruitment to the maternal-fetal interface.","method":"Chromatin immunoprecipitation, in vitro decidual cell models, siRNA for EZH2, hCG treatment, CD8 cell recruitment assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating H3K27me3 enrichment at CXCL10 promoter, EZH2 siRNA validation, functional cell recruitment readout; single lab","pmids":["32238853"],"is_preprint":false},{"year":1999,"finding":"Recombinant vaccinia viruses encoding CRG-2 (murine IP-10/CXCL10 homolog) conferred antiviral activity in vivo in athymic nude mice. Virus-encoded CRG-2 enhanced NK cell cytolytic activity 2- to 3-fold and increased splenic cellularity, with increased mononuclear cell infiltration in the liver. Control of viral replication required NK cells and type I IFNs (IFN-α, IFN-β) as established by neutralizing/depleting antibody experiments.","method":"Recombinant vaccinia virus expression system, in vivo infection model, NK cell depletion, IFN neutralizing antibodies","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with specific antibody depletions establishing NK and IFN dependency; single lab","pmids":["9882354"],"is_preprint":false},{"year":2009,"finding":"CXCL10 is constitutively expressed and stored in large dense-core vesicles in neurons, released constitutively at low levels. Neuronal CXCL10 expression is not regulated by injury or stress. In vivo CXCL10 peak expression during brain development correlates with the presence of CXCR3-expressing CD11b+ and GFAP+ glial cells, suggesting a role in glial recruitment/homing during embryogenesis.","method":"Immunohistochemistry, electron microscopy (vesicle localization), ELISA for secretion, in vivo developmental expression analysis","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization by electron microscopy with functional developmental correlation; single lab","pmids":["19919575"],"is_preprint":false},{"year":2022,"finding":"MEK inhibitor combined with PEM/CDDP chemotherapy triggers CXCL10 secretion by cancer cells through OPTN-dependent mitophagy in a mitochondrial DNA- and TLR9-dependent manner. TLR9 or autophagy/mitophagy inhibition abolished CXCL10 production and the anti-tumor efficacy of the combination therapy. This places TLR9 and mitophagy upstream of CXCL10 induction in this context.","method":"In vitro cancer cell treatment, genetic inhibition of TLR9 and autophagy/mitophagy genes, in vivo lung tumor models, OPTN knockout","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic dissection of mitophagy→TLR9→CXCL10 pathway with multiple in vivo and in vitro validations; single lab","pmids":["35051357"],"is_preprint":false},{"year":2023,"finding":"MLKL (mixed-lineage kinase domain-like protein) promotes CXCL10 secretion from pancreatic acinar cells, which in turn drives M1 macrophage polarization. Mlkl knockout mice showed reduced CXCL10 secretion and reduced M1 polarization during experimental pancreatitis. In vitro CXCL10 neutralization impaired the pro-M1 effect of conditioned medium from cerulein-treated acinar cells; in vivo CXCL10 neutralization reduced M1 polarization and AP severity. This effect was independent of RIPK3.","method":"Mlkl-/- and Ripk3-/- mice, in vitro neutralizing antibody, in vivo neutralizing antibody, conditioned medium experiments, flow cytometry for macrophage subtypes","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent knockout models plus antibody neutralization in vitro and in vivo; mechanistic pathway defined; single lab","pmids":["36828808"],"is_preprint":false},{"year":2007,"finding":"Palmitic acid (saturated FFA) induces CXCL10/IP-10 gene expression in human macrophages via NF-κB activation. Two structurally distinct NF-κB inhibitors blocked PA-induced IP-10 gene expression. Conditioned medium from PA-treated cells increased lymphocyte migration by 41%, which was significantly reduced by IP-10-neutralizing antibody.","method":"Gene expression analysis, NF-κB activity assay, pharmacological NF-κB inhibition, IP-10 neutralizing antibody, lymphocyte migration assay","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — NF-κB linkage shown by two inhibitors with functional consequence (lymphocyte migration); single lab, single method per step","pmids":["17467667"],"is_preprint":false},{"year":2018,"finding":"S. aureus downregulates IP-10/CXCL10 production in monocytes through activation of MAPKs p38 and ERK and inhibition of STAT1 signaling, reducing Th1 cell-recruiting chemokine production. This suppression is independent of peptidoglycan-induced IL-10. The net effect is inhibition of superantigen-induced Th1 cell recruitment.","method":"Monocyte stimulation assays, MAPK/STAT1 western blot, pharmacological pathway inhibitors, T cell chemotaxis assay","journal":"Journal of immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — signaling pathway identified but without specific genetic knockouts; single lab, indirect mechanistic dissection","pmids":["28122962"],"is_preprint":false},{"year":2018,"finding":"CXCL10 expression is determined by a subset of plasmacytoid dendritic cells (pDCs) following TLR7 stimulation. CXCL10 expression in dendritic cells requires IFNAR (type I IFN receptor) signaling; IFNAR blocking and deficiency abolished CXCR3 ligand expression in Flt3L-derived DCs. CXCL10+ and CXCL10- pDC populations are transcriptionally distinct, defining pDC heterogeneity.","method":"Chemokine reporter mouse, TLR7 stimulation, IFNAR blocking/deficiency, single-cell transcriptomics","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter mouse with receptor blocking and deficiency showing IFNAR dependence; transcriptional distinction confirmed; single lab","pmids":["29870118"],"is_preprint":false}],"current_model":"CXCL10 (IP-10) is an IFN-γ-inducible CXC chemokine that binds primarily to CXCR3 (and, in beta cells, TLR4) through a hydrophobic receptor-interaction surface involving N-loop and N-terminal residues (especially Arg-8 for signaling) partially overlapping with heparin-binding residues (centered on Arg-22); it signals through CXCR3 to activate Gα-coupled Ca2+ flux, cAMP/PKA, and MAPK (p38, ERK) pathways, driving T cell and NK cell chemotaxis, microglial activation, inhibition of angiogenesis (via suppression of VEGF and MMP-13), and induction of EMT in tumor contexts; its transcription is positively regulated by NF-κB, IRF3, STAT1 (via IFN-γ/JAK), NFAT/p38/JNK, and PKC, and negatively by epigenetic silencing through EZH2/G9a-mediated H3K27me3/H3K9me3 at its promoter; the mature protein can be inactivated by DPP4-mediated N-terminal truncation generating a CXCR3-binding but non-signaling antagonist, or by GP63 protease cleavage after A81."},"narrative":{"mechanistic_narrative":"CXCL10 (IP-10) is a CXC chemokine that orchestrates the recruitment and activation of immune cells, signaling principally through its shared receptor CXCR3 to drive activated T cell chemotaxis and reciprocal cross-desensitization with the related ligand CXCL9/Mig [PMID:9060447, PMID:10589690]. Structural and mutational studies define how the ligand engages its receptor: a hydrophobic cleft formed by the N-loop and 40s-loop contacts the CXCR3 N-terminus, while the N-terminal Arg-8 is critical for signaling and a partially overlapping but distinct surface centered on Arg-22 mediates heparin/GAG binding that is dispensable for CXCR3 engagement [PMID:12173928, PMID:12571234]; the protein can also assemble into a novel N-terminally-linked tetramer presenting heparin-binding sites at the dimer interfaces [PMID:18560148]. Through CXCR3 CXCL10 elevates intracellular Ca2+ and activates p38/ERK MAPK signaling, outputs that underlie diverse cellular consequences including synovial fibroblast invasion and MMP-1 induction in arthritis [PMID:21811993], increased neuronal excitability and neuropathic pain [PMID:33196963], anti-angiogenic suppression of endothelial migration via cAMP/PKA and the VEGF/MMP-13 axis [PMID:22815829, PMID:28623423], and accumulation of T cells and parasites in the CNS during infection [PMID:19827943]. Beyond CXCR3, CXCL10 acts through TLR4 in pancreatic beta cells to switch Akt/JNK signaling toward apoptosis and impair insulin secretion [PMID:19187771], and engages both CXCR3 and TLR4 in alveolar macrophages to induce CCL12 and promote premetastatic niche formation [PMID:35398531]. CXCL10 transcription is induced by IFN-γ, NF-κB, IRF3, NFAT, PKC, and stress-responsive PERK signaling [PMID:25342131, PMID:9705166, PMID:28855240, PMID:28233092, PMID:28065589] and repressed epigenetically by EZH2/G9a-mediated H3K27me3/H3K9me3 at its promoter [PMID:29053336, PMID:32238853]. The mature chemokine is post-translationally inactivated by DPP4-mediated N-terminal truncation, which generates a CXCR3-binding but non-signaling antagonist [PMID:30026741], and by the Leishmania protease GP63, which cleaves after Ala-81 to abolish chemotactic activity [PMID:31440475].","teleology":[{"year":1997,"claim":"Established CXCL10's target-cell selectivity and receptor sharing, answering which leukocytes it recruits and through what receptor.","evidence":"Recombinant IP-10 chemotaxis and cross-desensitization assays with CXCL9 in vitro and in vivo","pmids":["9060447"],"confidence":"High","gaps":["Did not define the structural basis of CXCR3 engagement","Anti-tumor and anti-angiogenic activities noted but not mechanistically dissected"]},{"year":1999,"claim":"Confirmed CXCR3-dependent functional signaling in non-leukocyte cells, extending CXCL10's action to resident tissue cells.","evidence":"Ca2+ flux and proliferation assays in CXCR3-expressing mesangial cells with recombinant IP-10","pmids":["10589690"],"confidence":"Medium","gaps":["Proliferative effect on mesangial cells not linked to downstream effectors","In vivo relevance to glomerulonephritis not directly tested"]},{"year":2002,"claim":"Defined the receptor-interaction surface of CXCL10, answering how the chemokine fold engages the CXCR3 N-terminus.","evidence":"NMR structure with CXCR3 N-terminal peptide titration","pmids":["12173928"],"confidence":"High","gaps":["No structure of the full ligand-receptor complex","Functional contribution of individual contact residues not tested in this study"]},{"year":2003,"claim":"Separated the CXCR3-signaling and heparin/GAG-binding determinants, resolving whether GAG binding is needed for receptor activation.","evidence":"Alanine-scanning mutagenesis with binding, chemotaxis, Ca2+, internalization assays and GAG-deficient CHO cells","pmids":["12571234"],"confidence":"High","gaps":["Performed on murine CXCL10; human residue equivalences inferred","Role of GAG binding in vivo for haptotactic gradients not addressed"]},{"year":2008,"claim":"Revealed a distinct oligomerization mode, addressing how CXCL10 may present multiple GAG-binding sites.","evidence":"X-ray crystallography of mouse IP-10","pmids":["18560148"],"confidence":"High","gaps":["Functional significance of the tetramer for signaling not established","Tetramer differs from human IP-10 forms; species relevance unclear"]},{"year":2009,"claim":"Identified a CXCR3-independent receptor (TLR4) and a pro-apoptotic signaling mode in beta cells, expanding CXCL10's receptor repertoire.","evidence":"Recombinant CXCL10 on human islets with CXCR3 blockade and Akt/JNK/PAK-2 western blots","pmids":["19187771"],"confidence":"Medium","gaps":["TLR4 not confirmed as a direct binding partner by binding assay","How CXCL10 engages TLR4 structurally is unknown"]},{"year":2009,"claim":"Defined CXCL10/CXCR3 as required for CNS T cell and parasite accumulation during infection, separating recruitment from systemic parasitemia.","evidence":"CXCL10-/- and CXCR3-/- mouse trypanosomiasis infection models","pmids":["19827943"],"confidence":"Medium","gaps":["Cellular source of brain CXCL10 not pinpointed","Single infection paradigm"]},{"year":2009,"claim":"Established constitutive neuronal storage and developmental expression, distinguishing inducible from constitutive CXCL10 pools.","evidence":"Immunohistochemistry, electron microscopy of dense-core vesicles, ELISA, developmental expression analysis","pmids":["19919575"],"confidence":"Medium","gaps":["Functional consequence of neuronal CXCL10 release not directly tested","Mechanism of constitutive secretion not defined"]},{"year":2012,"claim":"Mapped the anti-angiogenic mechanism to a C-terminal fragment acting via cAMP/PKA and calpain inhibition, defining a functional domain.","evidence":"Endothelial motility/tube formation and in vivo Matrigel assays with the IP-10p peptide and CXCR3 neutralization","pmids":["22815829"],"confidence":"Medium","gaps":["Whether the C-terminal fragment is generated physiologically not shown","Relationship to GAG-binding C-terminal residues unaddressed"]},{"year":2017,"claim":"Placed CXCL10 upstream of VEGF/MMP-13 suppression in vivo, ordering the anti-angiogenic pathway hierarchy.","evidence":"AAV9-driven CXCL10 overexpression, CXCL10/CXCR3 neutralization, MMP-13 inhibition in mouse cornea","pmids":["28623423"],"confidence":"Medium","gaps":["Direct molecular link from CXCR3 to VEGF/MMP-13 transcription not resolved","Single tissue model"]},{"year":2017,"claim":"Demonstrated context-dependent pro-tumor signaling (EMT/metastasis via MMP-2), contrasting with the anti-angiogenic role.","evidence":"shRNA, overexpression, Transwell, xenograft, microarray in hepatocellular carcinoma cells","pmids":["28670372"],"confidence":"Low","gaps":["CXCL10→MMP-2 connection identified only by microarray, not mechanistically validated","Receptor mediating the EMT effect not defined"]},{"year":2018,"claim":"Showed enzymatic generation of a CXCR3-binding non-signaling antagonist by DPP4, establishing a post-translational off-switch.","evidence":"Digital ELISA for agonist/antagonist forms, DPP4 activity assay, immunohistochemistry in TB lesions","pmids":["30026741"],"confidence":"Medium","gaps":["Antagonist potency at CXCR3 not quantified here","Causal role of antagonist in TB outcome correlative"]},{"year":2019,"claim":"Identified a pathogen protease (GP63) cleavage site at Ala-81 that inactivates chemotaxis, defining an immune-evasion mechanism.","evidence":"In vitro protease cleavage with site sequencing and T cell chemotaxis/CXCR3 signaling assays","pmids":["31440475"],"confidence":"High","gaps":["In vivo contribution to Leishmania persistence not demonstrated","Whether cleaved fragment retains any receptor binding not tested"]},{"year":null,"claim":"How CXCL10 discriminates among CXCR3, TLR4, and proteolytic regulation to produce opposing pro- versus anti-tumor and pro- versus anti-angiogenic outcomes in different tissues remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of CXCL10 bound to TLR4 or full-length CXCR3","Determinants of context-dependent functional switching not defined","Physiological generators of the anti-angiogenic C-terminal fragment unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,0,1,15]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,2]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,25,27]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,17,13,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,5,16,6]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[9,14,20,21,23]}],"complexes":[],"partners":["CXCR3","TLR4","DPP4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02778","full_name":"C-X-C motif chemokine 10","aliases":["10 kDa interferon gamma-induced protein","Gamma-IP10","IP-10","Small-inducible cytokine B10"],"length_aa":98,"mass_kda":10.9,"function":"Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects (PubMed:11157474, PubMed:22652417, PubMed:7540647). Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity). Mechanistically, binding of CXCL10 to the CXCR3 receptor activates G protein-mediated signaling and results in downstream activation of phospholipase C-dependent pathway, an increase in intracellular calcium production and actin reorganization (PubMed:12750173, PubMed:19151743). In turn, recruitment of activated Th1 lymphocytes occurs at sites of inflammation (PubMed:12663757, PubMed:12750173). Activation of the CXCL10/CXCR3 axis also plays an important role in neurons in response to brain injury for activating microglia, the resident macrophage population of the central nervous system, and directing them to the lesion site. This recruitment is an essential element for neuronal reorganization (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02778/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL10","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL10","total_profiled":1310},"omim":[{"mim_id":"621401","title":"DEAH-BOX HELICASE 35; DHX35","url":"https://www.omim.org/entry/621401"},{"mim_id":"620430","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 3; ADMIO3","url":"https://www.omim.org/entry/620430"},{"mim_id":"619872","title":"IMMUNODEFICIENCY 101 (VARICELLA ZOSTER VIRUS-SPECIFIC); IMD101","url":"https://www.omim.org/entry/619872"},{"mim_id":"618852","title":"AUTOINFLAMMATION WITH EPISODIC FEVER AND LYMPHADENOPATHY; AIEFL","url":"https://www.omim.org/entry/618852"},{"mim_id":"618172","title":"LONG NONCODING RNA UPREGULATOR OF ANTIVIRAL RESPONSE INTERFERON SIGNALING; LUARIS","url":"https://www.omim.org/entry/618172"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":90.0}],"url":"https://www.proteinatlas.org/search/CXCL10"},"hgnc":{"alias_symbol":["IFI10","IP-10","crg-2","mob-1","C7","gIP-10"],"prev_symbol":["INP10","SCYB10"]},"alphafold":{"accession":"P02778","domains":[{"cath_id":"2.40.50.40","chopping":"22-95","consensus_level":"high","plddt":92.3239,"start":22,"end":95}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02778","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02778-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02778-F1-predicted_aligned_error_v6.png","plddt_mean":89.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL10","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL10"},"sequence":{"accession":"P02778","fasta_url":"https://rest.uniprot.org/uniprotkb/P02778.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02778/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02778"}},"corpus_meta":[{"pmid":"21802343","id":"PMC_21802343","title":"CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.","date":"2011","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21802343","citation_count":657,"is_preprint":false},{"pmid":"9060447","id":"PMC_9060447","title":"Mig and IP-10: CXC chemokines that target lymphocytes.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9060447","citation_count":655,"is_preprint":false},{"pmid":"19105984","id":"PMC_19105984","title":"CXCL10 and autoimmune diseases.","date":"2008","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19105984","citation_count":293,"is_preprint":false},{"pmid":"35051357","id":"PMC_35051357","title":"MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.","date":"2022","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/35051357","citation_count":191,"is_preprint":false},{"pmid":"19187771","id":"PMC_19187771","title":"CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling.","date":"2009","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19187771","citation_count":186,"is_preprint":false},{"pmid":"29449068","id":"PMC_29449068","title":"Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29449068","citation_count":175,"is_preprint":false},{"pmid":"29893515","id":"PMC_29893515","title":"CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29893515","citation_count":166,"is_preprint":false},{"pmid":"2118520","id":"PMC_2118520","title":"Identification of CRG-2. An interferon-inducible mRNA predicted to encode a murine monokine.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2118520","citation_count":163,"is_preprint":false},{"pmid":"20059481","id":"PMC_20059481","title":"Islet inflammation and CXCL10 in recent-onset type 1 diabetes.","date":"2010","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20059481","citation_count":159,"is_preprint":false},{"pmid":"34593622","id":"PMC_34593622","title":"Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34593622","citation_count":140,"is_preprint":false},{"pmid":"8906829","id":"PMC_8906829","title":"Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-gamma with patterns of tissue expression that suggest nonredundant roles in vivo.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8906829","citation_count":120,"is_preprint":false},{"pmid":"25725102","id":"PMC_25725102","title":"CXCL10 triggers early microglial activation in the cuprizone model.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25725102","citation_count":117,"is_preprint":false},{"pmid":"24868552","id":"PMC_24868552","title":"The multifaceted functions of CXCL10 in cardiovascular disease.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24868552","citation_count":116,"is_preprint":false},{"pmid":"17943641","id":"PMC_17943641","title":"CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?","date":"2007","source":"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","url":"https://pubmed.ncbi.nlm.nih.gov/17943641","citation_count":114,"is_preprint":false},{"pmid":"12173928","id":"PMC_12173928","title":"The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12173928","citation_count":113,"is_preprint":false},{"pmid":"26042934","id":"PMC_26042934","title":"Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome.","date":"2015","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26042934","citation_count":113,"is_preprint":false},{"pmid":"24529741","id":"PMC_24529741","title":"CXCR3, CXCL10 and type 1 diabetes.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24529741","citation_count":103,"is_preprint":false},{"pmid":"10589690","id":"PMC_10589690","title":"Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis.","date":"1999","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10589690","citation_count":102,"is_preprint":false},{"pmid":"8301141","id":"PMC_8301141","title":"IFN and virus-inducible expression of an immediate early gene, crg-2/IP-10, and a delayed gene, I-A alpha in astrocytes and microglia.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8301141","citation_count":92,"is_preprint":false},{"pmid":"22366165","id":"PMC_22366165","title":"CXCL10: a candidate biomarker in transplantation.","date":"2012","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22366165","citation_count":92,"is_preprint":false},{"pmid":"23092582","id":"PMC_23092582","title":"The interaction between CXCL10 and cytokines in chronic inflammatory arthritis.","date":"2012","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23092582","citation_count":90,"is_preprint":false},{"pmid":"17467667","id":"PMC_17467667","title":"Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB activation.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17467667","citation_count":88,"is_preprint":false},{"pmid":"25605650","id":"PMC_25605650","title":"CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease.","date":"2015","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/25605650","citation_count":87,"is_preprint":false},{"pmid":"12571234","id":"PMC_12571234","title":"CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10).","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12571234","citation_count":87,"is_preprint":false},{"pmid":"9882354","id":"PMC_9882354","title":"The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9882354","citation_count":86,"is_preprint":false},{"pmid":"30472104","id":"PMC_30472104","title":"IP-10 is highly involved in HIV infection.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/30472104","citation_count":84,"is_preprint":false},{"pmid":"26405599","id":"PMC_26405599","title":"IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/26405599","citation_count":79,"is_preprint":false},{"pmid":"21811993","id":"PMC_21811993","title":"CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis.","date":"2011","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21811993","citation_count":78,"is_preprint":false},{"pmid":"22815829","id":"PMC_22815829","title":"An IP-10 (CXCL10)-derived peptide inhibits angiogenesis.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22815829","citation_count":77,"is_preprint":false},{"pmid":"21303517","id":"PMC_21303517","title":"Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.","date":"2011","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21303517","citation_count":72,"is_preprint":false},{"pmid":"25597826","id":"PMC_25597826","title":"IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy.","date":"2015","source":"The Journal of infection","url":"https://pubmed.ncbi.nlm.nih.gov/25597826","citation_count":69,"is_preprint":false},{"pmid":"36366543","id":"PMC_36366543","title":"CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections.","date":"2022","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/36366543","citation_count":68,"is_preprint":false},{"pmid":"17287085","id":"PMC_17287085","title":"Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis.","date":"2007","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/17287085","citation_count":68,"is_preprint":false},{"pmid":"19827943","id":"PMC_19827943","title":"Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis.","date":"2009","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/19827943","citation_count":65,"is_preprint":false},{"pmid":"37129929","id":"PMC_37129929","title":"KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2-CXCL10 Axis in Colorectal Cancer.","date":"2023","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/37129929","citation_count":63,"is_preprint":false},{"pmid":"28046003","id":"PMC_28046003","title":"CXCL10/IP-10 Neutralization Can Ameliorate Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Rats.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28046003","citation_count":61,"is_preprint":false},{"pmid":"33196963","id":"PMC_33196963","title":"CXCL10/CXCR3 Signaling in the DRG Exacerbates Neuropathic Pain in Mice.","date":"2020","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/33196963","citation_count":60,"is_preprint":false},{"pmid":"32089645","id":"PMC_32089645","title":"Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases.","date":"2020","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32089645","citation_count":55,"is_preprint":false},{"pmid":"32207043","id":"PMC_32207043","title":"CXCL-10: a new candidate for melanoma therapy?","date":"2020","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/32207043","citation_count":53,"is_preprint":false},{"pmid":"25342131","id":"PMC_25342131","title":"Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophages.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25342131","citation_count":52,"is_preprint":false},{"pmid":"9705166","id":"PMC_9705166","title":"Chemokine IP-10 expression in cultured human keratinocytes.","date":"1998","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/9705166","citation_count":52,"is_preprint":false},{"pmid":"29053336","id":"PMC_29053336","title":"Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.","date":"2018","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29053336","citation_count":51,"is_preprint":false},{"pmid":"36648332","id":"PMC_36648332","title":"Spatially resolved transcriptomics reveals pro-inflammatory fibroblast involved in lymphocyte recruitment through CXCL8 and CXCL10.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36648332","citation_count":48,"is_preprint":false},{"pmid":"26318079","id":"PMC_26318079","title":"CXCL10 in psoriasis.","date":"2015","source":"Advances in medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26318079","citation_count":47,"is_preprint":false},{"pmid":"24977661","id":"PMC_24977661","title":"IP-10 in autoimmune thyroiditis.","date":"2014","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/24977661","citation_count":45,"is_preprint":false},{"pmid":"30109979","id":"PMC_30109979","title":"Chemokine CXCL10 and Coronavirus-Induced Neurologic Disease.","date":"2018","source":"Viral immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30109979","citation_count":43,"is_preprint":false},{"pmid":"25386381","id":"PMC_25386381","title":"Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.","date":"2014","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/25386381","citation_count":42,"is_preprint":false},{"pmid":"15518041","id":"PMC_15518041","title":"IP-10 and type 1 diabetes: a question of time and location.","date":"2004","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/15518041","citation_count":41,"is_preprint":false},{"pmid":"17505511","id":"PMC_17505511","title":"Expression of IP-10 related to angiogenesis in uterine cervical cancers.","date":"2007","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17505511","citation_count":41,"is_preprint":false},{"pmid":"21155750","id":"PMC_21155750","title":"CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo.","date":"2011","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21155750","citation_count":39,"is_preprint":false},{"pmid":"28670372","id":"PMC_28670372","title":"CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28670372","citation_count":38,"is_preprint":false},{"pmid":"35398531","id":"PMC_35398531","title":"CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasis.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35398531","citation_count":38,"is_preprint":false},{"pmid":"28855240","id":"PMC_28855240","title":"Pancreatic β-Cell-Derived IP-10/CXCL10 Isletokine Mediates Early Loss of Graft Function in Islet Cell Transplantation.","date":"2017","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/28855240","citation_count":36,"is_preprint":false},{"pmid":"26892362","id":"PMC_26892362","title":"Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26892362","citation_count":36,"is_preprint":false},{"pmid":"36828808","id":"PMC_36828808","title":"MLKL signaling regulates macrophage polarization in acute pancreatitis through CXCL10.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36828808","citation_count":35,"is_preprint":false},{"pmid":"30026741","id":"PMC_30026741","title":"Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30026741","citation_count":35,"is_preprint":false},{"pmid":"28623423","id":"PMC_28623423","title":"CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13.","date":"2017","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28623423","citation_count":35,"is_preprint":false},{"pmid":"15108349","id":"PMC_15108349","title":"Regulation of neuroinflammation: the role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis.","date":"2004","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15108349","citation_count":35,"is_preprint":false},{"pmid":"29122683","id":"PMC_29122683","title":"High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection.","date":"2017","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29122683","citation_count":34,"is_preprint":false},{"pmid":"16309891","id":"PMC_16309891","title":"Significance of serum CXCL10/IP-10 level in type 1 diabetes.","date":"2005","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/16309891","citation_count":34,"is_preprint":false},{"pmid":"34123844","id":"PMC_34123844","title":"IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34123844","citation_count":33,"is_preprint":false},{"pmid":"36483597","id":"PMC_36483597","title":"Role of CXCL10 in Spinal Cord Injury.","date":"2022","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36483597","citation_count":32,"is_preprint":false},{"pmid":"25693758","id":"PMC_25693758","title":"Serum levels of leptin and IP-10 in preeclampsia compared to controls.","date":"2015","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/25693758","citation_count":32,"is_preprint":false},{"pmid":"37487374","id":"PMC_37487374","title":"FABP4 in LSECs promotes CXCL10-mediated macrophage recruitment and M1 polarization during NAFLD progression.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37487374","citation_count":31,"is_preprint":false},{"pmid":"8903850","id":"PMC_8903850","title":"Regulatory mechanisms of MuRantes and CRG-2 chemokine gene induction in central nervous system glial cells by virus.","date":"1995","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8903850","citation_count":31,"is_preprint":false},{"pmid":"31440475","id":"PMC_31440475","title":"Pathogen Evasion of Chemokine Response Through Suppression of CXCL10.","date":"2019","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31440475","citation_count":31,"is_preprint":false},{"pmid":"31666025","id":"PMC_31666025","title":"Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis.","date":"2019","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31666025","citation_count":30,"is_preprint":false},{"pmid":"38056897","id":"PMC_38056897","title":"CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38056897","citation_count":29,"is_preprint":false},{"pmid":"28065589","id":"PMC_28065589","title":"PERK and XBP1 differentially regulate CXCL10 and CCL2 production.","date":"2017","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/28065589","citation_count":27,"is_preprint":false},{"pmid":"30781765","id":"PMC_30781765","title":"Cell-Free DNA and CXCL10 Derived from Bronchoalveolar Lavage Predict Lung Transplant Survival.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30781765","citation_count":27,"is_preprint":false},{"pmid":"16490936","id":"PMC_16490936","title":"Expression of IP-10/CXCL10 is upregulated by double-stranded RNA in BEAS-2B bronchial epithelial cells.","date":"2006","source":"Respiration; international review of thoracic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16490936","citation_count":27,"is_preprint":false},{"pmid":"35795684","id":"PMC_35795684","title":"A Teleost CXCL10 Is Both an Immunoregulator and an Antimicrobial.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35795684","citation_count":26,"is_preprint":false},{"pmid":"28906016","id":"PMC_28906016","title":"CXCL10 is upregulated in synovium and cartilage following articular fracture.","date":"2017","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/28906016","citation_count":26,"is_preprint":false},{"pmid":"35897689","id":"PMC_35897689","title":"Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35897689","citation_count":26,"is_preprint":false},{"pmid":"36374433","id":"PMC_36374433","title":"Transcriptional expression of CXCL10 and STAT1 in lupus nephritis and the intervention effect of triptolide.","date":"2022","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/36374433","citation_count":25,"is_preprint":false},{"pmid":"27764787","id":"PMC_27764787","title":"PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27764787","citation_count":25,"is_preprint":false},{"pmid":"27241258","id":"PMC_27241258","title":"Targeting the IFN-γ/CXCL10 pathway in lichen planus.","date":"2016","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/27241258","citation_count":25,"is_preprint":false},{"pmid":"33221386","id":"PMC_33221386","title":"CXCL5, CXCL8, and CXCL10 regulation by bacteria and mechanical forces in periodontium.","date":"2020","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/33221386","citation_count":24,"is_preprint":false},{"pmid":"34534571","id":"PMC_34534571","title":"Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity.","date":"2021","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/34534571","citation_count":24,"is_preprint":false},{"pmid":"32238853","id":"PMC_32238853","title":"Human Chorionic Gonadotropin modulates CXCL10 Expression through Histone Methylation in human decidua.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32238853","citation_count":24,"is_preprint":false},{"pmid":"28122962","id":"PMC_28122962","title":"Staphylococcus aureus Downregulates IP-10 Production and Prevents Th1 Cell Recruitment.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28122962","citation_count":22,"is_preprint":false},{"pmid":"39190494","id":"PMC_39190494","title":"CXCL9, CXCL10, and CCL19 synergistically recruit T lymphocytes to skin in lichen planus.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39190494","citation_count":22,"is_preprint":false},{"pmid":"31285802","id":"PMC_31285802","title":"Urinary CXCL9 and CXCL10 Levels and Acute Renal Graft Rejection.","date":"2019","source":"International journal of organ transplantation medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31285802","citation_count":20,"is_preprint":false},{"pmid":"28142122","id":"PMC_28142122","title":"COMMD7 promotes hepatocellular carcinoma through regulating CXCL10.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28142122","citation_count":20,"is_preprint":false},{"pmid":"33472520","id":"PMC_33472520","title":"Impact of Plasma IP-10/CXCL10 and RANTES/CCL5 Levels on Neurocognitive Function in HIV Treatment-Naive Patients.","date":"2021","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/33472520","citation_count":19,"is_preprint":false},{"pmid":"23502337","id":"PMC_23502337","title":"Differential expression of CXCL1, CXCL9, CXCL10 and CXCL12 chemokines in alopecia areata.","date":"2013","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/23502337","citation_count":19,"is_preprint":false},{"pmid":"19919575","id":"PMC_19919575","title":"Expression of CXCL10 in cultured cortical neurons.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19919575","citation_count":19,"is_preprint":false},{"pmid":"38335607","id":"PMC_38335607","title":"The interplay of Cxcl10+/Mmp14+ monocytes and Ccl3+ neutrophils proactively mediates silica-induced pulmonary fibrosis.","date":"2024","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/38335607","citation_count":18,"is_preprint":false},{"pmid":"19131211","id":"PMC_19131211","title":"IP-10 protects while MIP-2 promotes experimental anesthetic hapten - induced hepatitis.","date":"2009","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19131211","citation_count":18,"is_preprint":false},{"pmid":"31232926","id":"PMC_31232926","title":"The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31232926","citation_count":18,"is_preprint":false},{"pmid":"30718282","id":"PMC_30718282","title":"The antiviral protein viperin regulates chondrogenic differentiation via CXCL10 protein secretion.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30718282","citation_count":17,"is_preprint":false},{"pmid":"8572251","id":"PMC_8572251","title":"Mob-1 expression in IL-2-induced ARDS: regulation by TNF-alpha.","date":"1995","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8572251","citation_count":17,"is_preprint":false},{"pmid":"34655920","id":"PMC_34655920","title":"The role of IP-10 and its receptor CXCR3 in early pregnancy.","date":"2021","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34655920","citation_count":16,"is_preprint":false},{"pmid":"35694534","id":"PMC_35694534","title":"Elevated IP-10 at the Protein and Gene Level Associates With Pulmonary TB.","date":"2022","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35694534","citation_count":16,"is_preprint":false},{"pmid":"29870118","id":"PMC_29870118","title":"Plasmacytoid dendritic cell heterogeneity is defined by CXCL10 expression following TLR7 stimulation.","date":"2018","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29870118","citation_count":16,"is_preprint":false},{"pmid":"18560148","id":"PMC_18560148","title":"Structure of mouse IP-10, a chemokine.","date":"2008","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/18560148","citation_count":16,"is_preprint":false},{"pmid":"19756997","id":"PMC_19756997","title":"Suppressive effect on MDC and IP-10 expression in monocytes by endocrine disruptor chemicals.","date":"2010","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/19756997","citation_count":16,"is_preprint":false},{"pmid":"17032164","id":"PMC_17032164","title":"Mx1 and IP-10: biomarkers to measure IFN-beta activity in mice following gene-based delivery.","date":"2006","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/17032164","citation_count":15,"is_preprint":false},{"pmid":"30273603","id":"PMC_30273603","title":"Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice.","date":"2018","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30273603","citation_count":15,"is_preprint":false},{"pmid":"28233092","id":"PMC_28233092","title":"Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.","date":"2017","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28233092","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52455,"output_tokens":9091,"usd":0.146865,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18746,"output_tokens":4040,"usd":0.097365,"stage2_stop_reason":"end_turn"},"total_usd":0.24423,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"The NMR structure of IP-10/CXCL10 was solved, revealing an unusual structural feature that may explain its ability to bind both CXCR3 and CCR3. The surface of IP-10 that interacts with the N-terminus of CXCR3 was defined and involves a hydrophobic cleft formed by the N-loop and 40s-loop region, similar to IL-8; an additional interaction region was identified at the N-terminus and 30s-loop of IP-10.\",\n      \"method\": \"NMR spectroscopy with CXCR3 N-terminal peptide titration\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure determination with functional receptor-binding surface mapping using peptide titration; single lab but multiple orthogonal validations\",\n      \"pmids\": [\"12173928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mutational analysis of murine IP-10/CXCL10 identified distinct but partially overlapping CXCR3 and heparin (GAG) binding sites. Arg-22 had the largest effect on heparin binding; residues Arg-20, Ile-24, Lys-26, Lys-46, and Lys-47 also contributed. Arg-8 (N-terminal, preceding first cysteine) was critical for CXCR3 signaling. GAG-deficient CHO cells showed that heparin/GAG binding is not required for CXCR3 binding and signaling.\",\n      \"method\": \"Extensive alanine-exchange mutagenesis with heparin binding, CXCR3 binding, chemotaxis, Ca2+ flux, and CXCR3 internalization assays; GAG-deficient CHO cell experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro mutagenesis with multiple orthogonal functional readouts (binding, signaling, chemotaxis, Ca2+ flux); extensive mutant panel\",\n      \"pmids\": [\"12571234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structure of mouse IP-10/CXCL10 revealed a novel tetrameric association in which two conventional CXC chemokine dimers associate through their N-terminal regions to form a 12-stranded elongated beta-sheet. This tetramer differs from previously described tetramers of human IP-10, platelet factor 4, and NAP-2. Two heparin-binding sites were identified at the interface of each of the two beta-sheet dimers.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure determination; single study but direct structural evidence\",\n      \"pmids\": [\"18560148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Recombinant human IP-10 (rIP-10) has no chemotactic activity on neutrophils but specifically targets lymphocytes, acting as a chemotactic factor for stimulated (but not resting) T cells. rIP-10 and rHuMig show reciprocal desensitization on activated T cells and share the receptor CXCR3. rIP-10 also inhibits neovascularization, inhibits hematopoietic progenitor cells, and exerts anti-tumor effects.\",\n      \"method\": \"Recombinant protein chemotaxis assays in vitro and in vivo; receptor desensitization assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — recombinant protein functional assays replicated across in vitro and in vivo settings, CXCR3 receptor sharing demonstrated by cross-desensitization\",\n      \"pmids\": [\"9060447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL10 impairs beta cell viability and function through TLR4 signaling rather than CXCR3. CXCL10 treatment of human islets decreased beta cell viability, impaired insulin secretion, and decreased insulin mRNA. Mechanistically, CXCL10 induced sustained activation of Akt and JNK and cleavage of PAK-2, switching Akt signals from proliferation to apoptosis. CXCR3 blockade did not abolish these effects, implicating TLR4 as a binding partner/receptor for CXCL10 in beta cells.\",\n      \"method\": \"Recombinant CXCL10 treatment of human islets; CXCR3 blockade experiments; western blotting for Akt, JNK, PAK-2 signaling\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab with multiple signaling readouts and receptor specificity tested, but TLR4 as direct binding partner not formally confirmed by binding assay\",\n      \"pmids\": [\"19187771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL10/CXCR3 signaling regulates synovial fibroblast (FLS) invasion in rheumatoid arthritis via an autocrine/paracrine mechanism. CXCL10 treatment increased FLS invasiveness 2-fold; anti-CXCR3 antibody and CXCR3 inhibitor AMG487 reduced invasiveness up to 77% in DA rat FLS and 58% in RA FLS. CXCR3 blockade reduced MMP-1 levels by 65%, inhibited intracellular calcium influx, and interfered with actin cytoskeleton reorganization and lamellipodia formation.\",\n      \"method\": \"Matrigel invasion assay, anti-CXCR3 antibody and pharmacological inhibitor treatment, MMP-1 ELISA, intracellular calcium measurement, actin cytoskeleton imaging\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays (invasion, MMP, Ca2+ flux, cytoskeleton), reciprocal pharmacological and antibody inhibition, single lab\",\n      \"pmids\": [\"21811993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL10 inhibits angiogenesis through CXCR3-dependent mechanisms involving cAMP production and PKA activation (inhibiting cell migration) and inhibition of VEGF-mediated m-calpain activation. A 21-amino-acid C-terminal alpha-helical fragment of IP-10 (residues 77-98, IP-10p) recapitulates these anti-angiogenic effects, inhibiting VEGF-induced endothelial motility and tube formation in vitro and vessel formation in vivo; CXCR3 neutralizing antibody blocked IP-10p effects.\",\n      \"method\": \"In vitro endothelial motility and tube formation assays; in vivo Matrigel plug assay; CXCR3 neutralizing antibody blockade; cAMP measurement; PKA activity assay; calpain activity assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo assays with defined peptide fragment and receptor blockade; single lab\",\n      \"pmids\": [\"22815829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CXCL10 triggers early microglial activation following oligodendrocyte apoptosis in the cuprizone model. CXCL10-deficient mice showed significantly reduced early microglial activation and ameliorated cuprizone toxicity. In vitro, recombinant CXCL10 induced migration and a pro-inflammatory phenotype in cultured microglia without affecting phagocytic activity or proliferation. In situ hybridization showed Cxcl10 mRNA is mainly expressed by astrocytes (and some oligodendrocytes) under these conditions.\",\n      \"method\": \"CXCL10-deficient knockout mice; in vitro recombinant CXCL10 treatment of microglia; genome-wide gene expression; in situ hybridization\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse model with defined phenotype, in vitro mechanistic follow-up with recombinant protein, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"25725102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 suppresses hem- and lymph-angiogenesis in inflamed corneas through suppression of angiogenic factors including VEGFa, VEGFc, and MMP-13 in vivo. AAV9-driven epithelial CXCL10 expression suppressed infection- and inflammation-induced angiogenesis; CXCL10 or CXCR3 neutralization promoted angiogenesis. Inhibition of MMP-13 (but not TIMPs) attenuated neovascularization, placing MMP-13 downstream of angiogenic signals but not upstream of CXCL10.\",\n      \"method\": \"AAV9 vector-driven CXCL10 overexpression; CXCL10 and CXCR3 neutralizing antibodies; MMP-13 inhibitors; in vivo mouse corneal model\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic/pharmacological manipulation with multiple readouts; single lab, pathway hierarchy tested\",\n      \"pmids\": [\"28623423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"EZH2 and G9a cooperatively repress CXCL10 expression in idiopathic pulmonary fibrosis fibroblasts through histone H3K27 trimethylation and H3K9 methylation at the CXCL10 promoter. EZH2 and G9a physically interact; knockdown of either reduces the other's histone mark and restores CXCL10 expression. TGF-β1 induces this epigenetic repression. Re-ChIP and proximity ligation assays confirmed co-occupancy of EZH2 and G9a at the CXCL10 promoter.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), Re-ChIP, proximity ligation assay, siRNA knockdown, pharmacological inhibition, promoter analysis\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP/Re-ChIP with mutagenesis-equivalent knockdown and multiple orthogonal methods (PLA, pharmacological inhibition), single lab\",\n      \"pmids\": [\"29053336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IP-10/CXCL10 gene induction in pancreatic beta cells is regulated by NFAT signaling via calcineurin-dependent pathways in response to oxidative or inflammatory stress. Sustained NFAT and p300 histone acetyltransferase association with the IP-10 gene promoter requires p38 and JNK MAPK activity, which differentially regulate IP-10 expression and protein release.\",\n      \"method\": \"Transgenic mouse studies, in vitro signaling pathway analysis, NFAT/p300 ChIP, MAPK inhibition\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple approaches (transgenic mice, ChIP, pharmacological inhibition) in single lab\",\n      \"pmids\": [\"28855240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Leishmania major virulence factor GP63 (glycoprotein-63) cleaves CXCL10 after amino acid A81 at the base of its C-terminal alpha-helix, inactivating its chemotactic function. This cleavage is specific to CXCR3-binding chemokines (CXCL10 and homologs) but not to distantly related chemokines (CXCL8, CCL22). The cleaved CXCL10 cannot signal through CXCR3 and fails to support T cell chemotaxis in vitro.\",\n      \"method\": \"In vitro protease cleavage assay, site identification by sequencing, T cell chemotaxis assay, CXCR3 signaling assay\",\n      \"journal\": \"Frontiers in cellular and infection microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of protease cleavage with exact cleavage site identification, functional consequence confirmed by T cell chemotaxis assay\",\n      \"pmids\": [\"31440475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DPP4 (CD26) can N-terminally truncate CXCL10 to generate an antagonist form capable of binding CXCR3 but unable to induce signaling. In tuberculosis lesions, higher levels of antagonist CXCL10 and reduced DPP4 enzyme activity were found in plasma of TB patients; DPP4-positive T cells were associated with CXCL10-secreting multinucleated giant cells, suggesting membrane-bound DPP4 can inactivate secreted CXCL10 locally.\",\n      \"method\": \"Simoa digital ELISA for agonist/antagonist CXCL10, DPP4 enzyme activity assay, immunohistochemistry, confocal microscopy\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — distinct quantification of agonist vs antagonist forms, enzyme activity measurement, and spatial co-localization; single lab\",\n      \"pmids\": [\"30026741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MRP8/MRP14 (S100A8/A9), an endogenous DAMP, induces IP-10/CXCL10 expression in monocytes/macrophages via TLR4 and TRIF (not MyD88). Full IP-10 induction requires synergistic activation of NF-κB and IRF3 transcription factors. MRP8/MRP14-induced chemotaxis of CXCR3+ cells was dependent on IP-10 production.\",\n      \"method\": \"THP-1 cell stimulation, TLR4/MyD88/TRIF pathway dissection, NF-κB and IRF3 reporter/western blot, neutralizing antibody, in vivo mouse trauma/hemorrhagic shock model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — signaling pathway dissection with receptor knockdown/blockade and in vivo validation; single lab\",\n      \"pmids\": [\"25342131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In human keratinocytes, IFN-γ induces IP-10 mRNA accumulation in a time- and dose-dependent manner. Superexpression occurs with IFN-γ combined with TNF-α or IL-1. Nuclear run-on experiments showed constitutively high IP-10 gene transcription in unstimulated keratinocytes not further increased by IFN-γ/TNF-α, indicating post-transcriptional regulation. PKC inhibitor H7 decreased IP-10 mRNA accumulation, implicating PKC in IP-10 expression regulation.\",\n      \"method\": \"RT-PCR, Northern blot, nuclear run-on transcription assay, HPLC protein isolation, ELISA, PKC inhibitor treatment\",\n      \"journal\": \"Archives of dermatological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nuclear run-on assays to distinguish transcriptional vs post-transcriptional regulation, pharmacological pathway dissection; single lab\",\n      \"pmids\": [\"9705166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IP-10 (CXCL10) and Mig (CXCL9) sharing of receptor CXCR3 was confirmed in glomerulonephritis; IP-10 induced intracellular Ca2+ influx in mesangial cells expressing CXCR3 and directly induced mesangial cell proliferation.\",\n      \"method\": \"Flow cytometry (CXCR3 expression), intracellular Ca2+ flux measurement, cell proliferation assay with recombinant IP-10\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional receptor activation (Ca2+ flux) and proliferation assay with recombinant ligand; single lab\",\n      \"pmids\": [\"10589690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CXCL10/CXCR3 signaling in dorsal root ganglion (DRG) neurons increases neuronal excitability and contributes to neuropathic pain. CXCL10 increased the number of action potentials in DRG neurons via CXCR3 (not increased in Cxcr3-/- neurons). CXCL10 activated p38 and ERK in DRG neurons; p38 inhibitor SB203580 decreased CXCL10-induced APs. Intra-DRG Cxcr3 shRNA attenuated spinal nerve ligation-induced mechanical allodynia and heat hyperalgesia.\",\n      \"method\": \"Electrophysiology (action potential recording), Cxcr3 knockout mice, shRNA knockdown, p38/ERK western blot, pharmacological inhibition\",\n      \"journal\": \"Neuroscience bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — electrophysiology with genetic knockout and shRNA confirmation, signaling pathway identified with pharmacological inhibition; single lab\",\n      \"pmids\": [\"33196963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Infected CXCL10-/- or CXCR3-/- mice demonstrated reduced accumulation of trypanosomes and T cells in the brain parenchyma during experimental African trypanosomiasis, while parasitemia levels were similar to wild-type, establishing that IFN-γ-dependent CXCL10/CXCR3 signaling is critical for brain parenchymal T cell and parasite accumulation specifically.\",\n      \"method\": \"CXCL10-/- and CXCR3-/- knockout mouse infection model, tissue cell quantification, parasitemia measurement, CXCL10 ELISA\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent knockout models (CXCL10-/- and CXCR3-/-) with consistent phenotype; single lab\",\n      \"pmids\": [\"19827943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 accelerates epithelial-mesenchymal transition (EMT) and metastasis of hepatocellular carcinoma cells via activation of MMP-2 expression. CXCL10 overexpression enhanced migration, invasion, and metastasis in vitro and in vivo; CXCL10 silencing inhibited these. Microarray analysis identified MMP-2 as a downstream factor of CXCL10.\",\n      \"method\": \"shRNA knockdown, overexpression, Transwell migration/invasion assay, in vivo xenograft, microarray gene expression analysis\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, microarray-based identification of MMP-2 as downstream target without direct mechanistic validation of the CXCL10→MMP-2 connection\",\n      \"pmids\": [\"28670372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Viperin regulates chondrogenic differentiation via CXCL10 secretion, which in turn modulates TGF-β/SMAD2/3 signaling activity in chondrocytes. Disturbances in this viperin-CXCL10-TGF-β/SMAD2/3 axis were observed in cartilage-hair hypoplasia (CHH) chondrocytic cells.\",\n      \"method\": \"siRNA knockdown, overexpression, ELISA, label-free MS proteomics, promoter reporter assays, immunoblotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (proteomics, siRNA, ELISA, reporter assays) linking viperin→CXCL10→TGF-β/SMAD2/3 axis; single lab\",\n      \"pmids\": [\"30718282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"JAK2V617F mutation drives cell-autonomous CXCL10 expression through NF-κB signaling. Pharmacological inhibition of mutated JAK2 kinase inhibits CXCL10 expression. NFκB is activated downstream of JAK2V617F and directly induces CXCL10 transcription, as demonstrated by luciferase reporter assays and ChIP.\",\n      \"method\": \"Cytokine array, qPCR, JAK inhibitor treatment, NF-κB luciferase reporter, ChIP, western blotting, immunofluorescence; Ba/F3 cells lacking CXCL10 receptor to exclude autocrine signaling\",\n      \"journal\": \"Journal of cancer research and clinical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (reporter, ChIP, pharmacological inhibition) demonstrating JAK2V617F→NF-κB→CXCL10 axis; single lab\",\n      \"pmids\": [\"28233092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PERK pathway positively regulates CXCL10 expression under ER stress conditions, while XBP1 (activated by IRE1α) negatively regulates it. PERK knockdown attenuated ER stress-induced CXCL10 mRNA expression associated with decreased NF-κB RelA and STAT3 phosphorylation; XBP1 knockdown enhanced CXCL10 expression with increased NF-κB RelA and STAT3 phosphorylation. Blockade of NF-κB or STAT3 markedly diminished CXCL10 expression.\",\n      \"method\": \"siRNA knockdown of PERK and XBP1, NF-κB and STAT3 pharmacological inhibition, RT-PCR, ELISA, western blot\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown of pathway components with multiple downstream readouts confirming NF-κB and STAT3 as mediators; single lab\",\n      \"pmids\": [\"28065589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL10 induces CCL12 expression in alveolar macrophages (AMs) by activating both CXCR3 and TLR4, promoting premetastatic niche formation. CXCR3/TLR4 deficiency or inhibition reduces CCL12 expression and subsequent monocytic MDSC recruitment. Ube2o is a negative modulator of CXCL10-induced CCL12 expression; its downregulation under tumor conditions enhances TAK1-NF-κB/ERK/JNK signaling and CXCL10-induced CCL12 expression by promoting TRAF6 polyubiquitination and inhibiting DDX3X degradation.\",\n      \"method\": \"CXCR3/TLR4 knockout mice, siRNA, pharmacological inhibition, western blot for signaling intermediates, in vivo lung metastasis model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dual receptor (CXCR3 and TLR4) signaling demonstrated with knockouts and pharmacological inhibition, mechanistic pathway defined; single lab\",\n      \"pmids\": [\"35398531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Human chorionic gonadotropin (hCG) inhibits CXCL10 expression in decidual stromal cells by inducing H3K27me3 histone methylation at Region 4 of the CXCL10 promoter, mediated through EZH2 (a member of the PRC2 complex). This regulation has functional consequences for CD8 cell recruitment to the maternal-fetal interface.\",\n      \"method\": \"Chromatin immunoprecipitation, in vitro decidual cell models, siRNA for EZH2, hCG treatment, CD8 cell recruitment assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating H3K27me3 enrichment at CXCL10 promoter, EZH2 siRNA validation, functional cell recruitment readout; single lab\",\n      \"pmids\": [\"32238853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Recombinant vaccinia viruses encoding CRG-2 (murine IP-10/CXCL10 homolog) conferred antiviral activity in vivo in athymic nude mice. Virus-encoded CRG-2 enhanced NK cell cytolytic activity 2- to 3-fold and increased splenic cellularity, with increased mononuclear cell infiltration in the liver. Control of viral replication required NK cells and type I IFNs (IFN-α, IFN-β) as established by neutralizing/depleting antibody experiments.\",\n      \"method\": \"Recombinant vaccinia virus expression system, in vivo infection model, NK cell depletion, IFN neutralizing antibodies\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with specific antibody depletions establishing NK and IFN dependency; single lab\",\n      \"pmids\": [\"9882354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL10 is constitutively expressed and stored in large dense-core vesicles in neurons, released constitutively at low levels. Neuronal CXCL10 expression is not regulated by injury or stress. In vivo CXCL10 peak expression during brain development correlates with the presence of CXCR3-expressing CD11b+ and GFAP+ glial cells, suggesting a role in glial recruitment/homing during embryogenesis.\",\n      \"method\": \"Immunohistochemistry, electron microscopy (vesicle localization), ELISA for secretion, in vivo developmental expression analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization by electron microscopy with functional developmental correlation; single lab\",\n      \"pmids\": [\"19919575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MEK inhibitor combined with PEM/CDDP chemotherapy triggers CXCL10 secretion by cancer cells through OPTN-dependent mitophagy in a mitochondrial DNA- and TLR9-dependent manner. TLR9 or autophagy/mitophagy inhibition abolished CXCL10 production and the anti-tumor efficacy of the combination therapy. This places TLR9 and mitophagy upstream of CXCL10 induction in this context.\",\n      \"method\": \"In vitro cancer cell treatment, genetic inhibition of TLR9 and autophagy/mitophagy genes, in vivo lung tumor models, OPTN knockout\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic dissection of mitophagy→TLR9→CXCL10 pathway with multiple in vivo and in vitro validations; single lab\",\n      \"pmids\": [\"35051357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MLKL (mixed-lineage kinase domain-like protein) promotes CXCL10 secretion from pancreatic acinar cells, which in turn drives M1 macrophage polarization. Mlkl knockout mice showed reduced CXCL10 secretion and reduced M1 polarization during experimental pancreatitis. In vitro CXCL10 neutralization impaired the pro-M1 effect of conditioned medium from cerulein-treated acinar cells; in vivo CXCL10 neutralization reduced M1 polarization and AP severity. This effect was independent of RIPK3.\",\n      \"method\": \"Mlkl-/- and Ripk3-/- mice, in vitro neutralizing antibody, in vivo neutralizing antibody, conditioned medium experiments, flow cytometry for macrophage subtypes\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent knockout models plus antibody neutralization in vitro and in vivo; mechanistic pathway defined; single lab\",\n      \"pmids\": [\"36828808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Palmitic acid (saturated FFA) induces CXCL10/IP-10 gene expression in human macrophages via NF-κB activation. Two structurally distinct NF-κB inhibitors blocked PA-induced IP-10 gene expression. Conditioned medium from PA-treated cells increased lymphocyte migration by 41%, which was significantly reduced by IP-10-neutralizing antibody.\",\n      \"method\": \"Gene expression analysis, NF-κB activity assay, pharmacological NF-κB inhibition, IP-10 neutralizing antibody, lymphocyte migration assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — NF-κB linkage shown by two inhibitors with functional consequence (lymphocyte migration); single lab, single method per step\",\n      \"pmids\": [\"17467667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"S. aureus downregulates IP-10/CXCL10 production in monocytes through activation of MAPKs p38 and ERK and inhibition of STAT1 signaling, reducing Th1 cell-recruiting chemokine production. This suppression is independent of peptidoglycan-induced IL-10. The net effect is inhibition of superantigen-induced Th1 cell recruitment.\",\n      \"method\": \"Monocyte stimulation assays, MAPK/STAT1 western blot, pharmacological pathway inhibitors, T cell chemotaxis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — signaling pathway identified but without specific genetic knockouts; single lab, indirect mechanistic dissection\",\n      \"pmids\": [\"28122962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL10 expression is determined by a subset of plasmacytoid dendritic cells (pDCs) following TLR7 stimulation. CXCL10 expression in dendritic cells requires IFNAR (type I IFN receptor) signaling; IFNAR blocking and deficiency abolished CXCR3 ligand expression in Flt3L-derived DCs. CXCL10+ and CXCL10- pDC populations are transcriptionally distinct, defining pDC heterogeneity.\",\n      \"method\": \"Chemokine reporter mouse, TLR7 stimulation, IFNAR blocking/deficiency, single-cell transcriptomics\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter mouse with receptor blocking and deficiency showing IFNAR dependence; transcriptional distinction confirmed; single lab\",\n      \"pmids\": [\"29870118\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL10 (IP-10) is an IFN-γ-inducible CXC chemokine that binds primarily to CXCR3 (and, in beta cells, TLR4) through a hydrophobic receptor-interaction surface involving N-loop and N-terminal residues (especially Arg-8 for signaling) partially overlapping with heparin-binding residues (centered on Arg-22); it signals through CXCR3 to activate Gα-coupled Ca2+ flux, cAMP/PKA, and MAPK (p38, ERK) pathways, driving T cell and NK cell chemotaxis, microglial activation, inhibition of angiogenesis (via suppression of VEGF and MMP-13), and induction of EMT in tumor contexts; its transcription is positively regulated by NF-κB, IRF3, STAT1 (via IFN-γ/JAK), NFAT/p38/JNK, and PKC, and negatively by epigenetic silencing through EZH2/G9a-mediated H3K27me3/H3K9me3 at its promoter; the mature protein can be inactivated by DPP4-mediated N-terminal truncation generating a CXCR3-binding but non-signaling antagonist, or by GP63 protease cleavage after A81.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CXCL10 (IP-10) is a CXC chemokine that orchestrates the recruitment and activation of immune cells, signaling principally through its shared receptor CXCR3 to drive activated T cell chemotaxis and reciprocal cross-desensitization with the related ligand CXCL9/Mig [#3, #15]. Structural and mutational studies define how the ligand engages its receptor: a hydrophobic cleft formed by the N-loop and 40s-loop contacts the CXCR3 N-terminus, while the N-terminal Arg-8 is critical for signaling and a partially overlapping but distinct surface centered on Arg-22 mediates heparin/GAG binding that is dispensable for CXCR3 engagement [#0, #1]; the protein can also assemble into a novel N-terminally-linked tetramer presenting heparin-binding sites at the dimer interfaces [#2]. Through CXCR3 CXCL10 elevates intracellular Ca2+ and activates p38/ERK MAPK signaling, outputs that underlie diverse cellular consequences including synovial fibroblast invasion and MMP-1 induction in arthritis [#5], increased neuronal excitability and neuropathic pain [#16], anti-angiogenic suppression of endothelial migration via cAMP/PKA and the VEGF/MMP-13 axis [#6, #8], and accumulation of T cells and parasites in the CNS during infection [#17]. Beyond CXCR3, CXCL10 acts through TLR4 in pancreatic beta cells to switch Akt/JNK signaling toward apoptosis and impair insulin secretion [#4], and engages both CXCR3 and TLR4 in alveolar macrophages to induce CCL12 and promote premetastatic niche formation [#22]. CXCL10 transcription is induced by IFN-\\u03b3, NF-\\u03baB, IRF3, NFAT, PKC, and stress-responsive PERK signaling [#13, #14, #10, #20, #21] and repressed epigenetically by EZH2/G9a-mediated H3K27me3/H3K9me3 at its promoter [#9, #23]. The mature chemokine is post-translationally inactivated by DPP4-mediated N-terminal truncation, which generates a CXCR3-binding but non-signaling antagonist [#12], and by the Leishmania protease GP63, which cleaves after Ala-81 to abolish chemotactic activity [#11].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established CXCL10's target-cell selectivity and receptor sharing, answering which leukocytes it recruits and through what receptor.\",\n      \"evidence\": \"Recombinant IP-10 chemotaxis and cross-desensitization assays with CXCL9 in vitro and in vivo\",\n      \"pmids\": [\"9060447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural basis of CXCR3 engagement\", \"Anti-tumor and anti-angiogenic activities noted but not mechanistically dissected\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Confirmed CXCR3-dependent functional signaling in non-leukocyte cells, extending CXCL10's action to resident tissue cells.\",\n      \"evidence\": \"Ca2+ flux and proliferation assays in CXCR3-expressing mesangial cells with recombinant IP-10\",\n      \"pmids\": [\"10589690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Proliferative effect on mesangial cells not linked to downstream effectors\", \"In vivo relevance to glomerulonephritis not directly tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the receptor-interaction surface of CXCL10, answering how the chemokine fold engages the CXCR3 N-terminus.\",\n      \"evidence\": \"NMR structure with CXCR3 N-terminal peptide titration\",\n      \"pmids\": [\"12173928\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the full ligand-receptor complex\", \"Functional contribution of individual contact residues not tested in this study\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Separated the CXCR3-signaling and heparin/GAG-binding determinants, resolving whether GAG binding is needed for receptor activation.\",\n      \"evidence\": \"Alanine-scanning mutagenesis with binding, chemotaxis, Ca2+, internalization assays and GAG-deficient CHO cells\",\n      \"pmids\": [\"12571234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Performed on murine CXCL10; human residue equivalences inferred\", \"Role of GAG binding in vivo for haptotactic gradients not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed a distinct oligomerization mode, addressing how CXCL10 may present multiple GAG-binding sites.\",\n      \"evidence\": \"X-ray crystallography of mouse IP-10\",\n      \"pmids\": [\"18560148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of the tetramer for signaling not established\", \"Tetramer differs from human IP-10 forms; species relevance unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified a CXCR3-independent receptor (TLR4) and a pro-apoptotic signaling mode in beta cells, expanding CXCL10's receptor repertoire.\",\n      \"evidence\": \"Recombinant CXCL10 on human islets with CXCR3 blockade and Akt/JNK/PAK-2 western blots\",\n      \"pmids\": [\"19187771\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TLR4 not confirmed as a direct binding partner by binding assay\", \"How CXCL10 engages TLR4 structurally is unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined CXCL10/CXCR3 as required for CNS T cell and parasite accumulation during infection, separating recruitment from systemic parasitemia.\",\n      \"evidence\": \"CXCL10-/- and CXCR3-/- mouse trypanosomiasis infection models\",\n      \"pmids\": [\"19827943\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular source of brain CXCL10 not pinpointed\", \"Single infection paradigm\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established constitutive neuronal storage and developmental expression, distinguishing inducible from constitutive CXCL10 pools.\",\n      \"evidence\": \"Immunohistochemistry, electron microscopy of dense-core vesicles, ELISA, developmental expression analysis\",\n      \"pmids\": [\"19919575\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of neuronal CXCL10 release not directly tested\", \"Mechanism of constitutive secretion not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapped the anti-angiogenic mechanism to a C-terminal fragment acting via cAMP/PKA and calpain inhibition, defining a functional domain.\",\n      \"evidence\": \"Endothelial motility/tube formation and in vivo Matrigel assays with the IP-10p peptide and CXCR3 neutralization\",\n      \"pmids\": [\"22815829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the C-terminal fragment is generated physiologically not shown\", \"Relationship to GAG-binding C-terminal residues unaddressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed CXCL10 upstream of VEGF/MMP-13 suppression in vivo, ordering the anti-angiogenic pathway hierarchy.\",\n      \"evidence\": \"AAV9-driven CXCL10 overexpression, CXCL10/CXCR3 neutralization, MMP-13 inhibition in mouse cornea\",\n      \"pmids\": [\"28623423\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link from CXCR3 to VEGF/MMP-13 transcription not resolved\", \"Single tissue model\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated context-dependent pro-tumor signaling (EMT/metastasis via MMP-2), contrasting with the anti-angiogenic role.\",\n      \"evidence\": \"shRNA, overexpression, Transwell, xenograft, microarray in hepatocellular carcinoma cells\",\n      \"pmids\": [\"28670372\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"CXCL10\\u2192MMP-2 connection identified only by microarray, not mechanistically validated\", \"Receptor mediating the EMT effect not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed enzymatic generation of a CXCR3-binding non-signaling antagonist by DPP4, establishing a post-translational off-switch.\",\n      \"evidence\": \"Digital ELISA for agonist/antagonist forms, DPP4 activity assay, immunohistochemistry in TB lesions\",\n      \"pmids\": [\"30026741\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antagonist potency at CXCR3 not quantified here\", \"Causal role of antagonist in TB outcome correlative\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified a pathogen protease (GP63) cleavage site at Ala-81 that inactivates chemotaxis, defining an immune-evasion mechanism.\",\n      \"evidence\": \"In vitro protease cleavage with site sequencing and T cell chemotaxis/CXCR3 signaling assays\",\n      \"pmids\": [\"31440475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution to Leishmania persistence not demonstrated\", \"Whether cleaved fragment retains any receptor binding not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CXCL10 discriminates among CXCR3, TLR4, and proteolytic regulation to produce opposing pro- versus anti-tumor and pro- versus anti-angiogenic outcomes in different tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of CXCL10 bound to TLR4 or full-length CXCR3\", \"Determinants of context-dependent functional switching not defined\", \"Physiological generators of the anti-angiogenic C-terminal fragment unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 0, 1, 15]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 25, 27]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 17, 13, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 5, 16, 6]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [9, 14, 20, 21, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CXCR3\", \"TLR4\", \"DPP4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}